Secure Data Is FAIR(er) Data

技术

网络安全和隐私 - 数据库安全
平台即服务 (PaaS) - 数据管理平台

适用行业

生命科学
药品

适用功能

产品研发

服务

数据科学服务
系统集成

挑战

Biopharmaceutical companies are facing the challenge of managing and utilizing their R&D data, which is often siloed within different functions of the company. This siloed data structure hinders the effective federation of distributed data, which is crucial for increasing clinical trial success rates. The industry is recognizing the value of sharing and reusing data for multiple analyses, which requires breaking down these data silos. Furthermore, the data generated in biopharmaceutical R&D is complex and originates from various sources, making it crucial to implement the FAIR (Findable, Accessible, Interoperable, and Reusable) principles for scientific data management and stewardship. However, making data FAIR is not an easy task and requires the right infrastructure that can handle the data volume and privacy of patient-level information.

关于客户

The customer in this case study is the biopharmaceutical industry at large. Biopharmaceutical companies are involved in the research, development, and production of pharmaceutical drugs based on biological sources. These companies generate a large amount of R&D data, which is a strategic asset used to build a more accurate and meaningful picture of targets, molecules, patients, and their responses to drugs. The data originates from a variety of sources, including internal databases, external collaborations, and public repositories. The industry is recognizing the value of sharing and reusing data for multiple analyses, which requires breaking down data silos. However, the data generated in biopharmaceutical R&D is complex and requires the implementation of the FAIR principles for scientific data management and stewardship.

解决方案

The solution to these challenges is a three-step process. The first step is to break down data silos to build an institutional memory for all data and make data-informed decisions. This can foster early go/no-go decisions, reduce drug development times, and decrease the number of costly late-stage failures. The second step is to make data FAIR. This involves implementing new data management approaches to centralize and massively harmonize the enormous amount of R&D data, which provides human access to high-quality integrated data and digital technologies. The third step is to keep data secure. This is particularly important for clinical trials that must comply with informed consent policies. The Genedata Profiler software solution is used to break down data silos and serve as the single source of truth for all translational and clinical research data, keeping data secure and FAIR.

运营影响

Breaking down data silos helps companies build an institutional memory for all their data and make data-informed decisions.
Making data FAIR amplifies the value of data assets and enables the generation of new insights quickly.
Implementing a data infrastructure that maintains FAIR data and keeps patient-level data secure allows biopharma organizations to perform research in regulatory-regulated environments.